levoleucovorin has been researched along with Carcinoma--Intraductal--Noninfiltrating* in 3 studies
3 other study(ies) available for levoleucovorin and Carcinoma--Intraductal--Noninfiltrating
| Article | Year |
|---|---|
Adjuvant chemotherapy in high-risk breast cancer patients with ten or more positive lymph nodes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Methotrexate; Middle Aged; Vinblastine | 1992 |
Osmotic blood-brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening.
Chemotherapeutic drug delivery can be enhanced by administering drugs into the internal carotid or vertebral artery circulation after osmotic opening of the blood-brain barrier (BBB). As evidence of the clinical implications of this technique, radiographic documentation of central nervous system (CNS) tumor regression was observed in three patients concurrent with the development of new tumor nodule(s) in portions of the brain distant from the region of osmotic blood-brain barrier opening. These three patients, one with metastatic carcinoma of the breast, one with glioblastoma, and one with primary CNS lymphoma, highlight the importance of drug delivery to CNS malignancies. Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Cyclophosphamide; Female; Glioma; Humans; Leucovorin; Lymphoma; Male; Mannitol; Methotrexate; Procarbazine; Tomography, X-Ray Computed; Water-Electrolyte Balance | 1984 |
Case report: management of methotrexate toxicity in an anephric patient.
We describe the case of an anephric woman on chronic hemodialysis who developed breast cancer with positive axillary nodes. After mastectomy, we attempted to treat her with adjuvant chemotherapy. She suffered severe toxicity involving the skin, gastrointestinal tract and bone marrow after a single dose of 15 mg (10 mg m-2) of methotrexate. She received high doses of leukovorin and hemodialysis was continued. Although hemodialysis caused little acute change in the serum methotrexate levels, over a period of 3 weeks the levels did decrease, her symptoms of toxicity subsided, and she recovered. The case demonstrates the limited effectiveness of hemodialysis for treating methotrexate toxicity and suggests that leukovorin is useful for reversing it. Topics: Adult; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Female; Humans; Leucovorin; Methotrexate; Nephrectomy; Renal Dialysis | 1982 |